{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T05:38:26Z","timestamp":1790314706007,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.clinthera.2024.09.010","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:50:39Z","timestamp":1729039839000},"page":"1016-1023","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews"],"prefix":"10.1016","volume":"46","author":[{"given":"Dana","family":"DiBenedetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Neme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Pan-Petesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemieke","family":"Willemze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tung","family":"Wynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nana","family":"Kragh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2024.09.010_bib0001","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0002","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0003","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/hae.14455","article-title":"rFIXFc prophylaxis improves pain and levels of physical activity in haemophilia B: post hoc analysis of B-LONG using haemophilia-specific quality of life questionnaires","volume":"28","author":"Astermark","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0004","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-021-00278-x","article-title":"Haemophilia","volume":"7","author":"Berntorp","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2024.09.010_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0006","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1111\/hae.14866","article-title":"Targeting higher factor VIII levels for prophylaxis in haemophilia A: a narrative review","volume":"29","author":"Malec","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0007","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.3324\/haematol.2019.241554","article-title":"Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model","volume":"106","author":"Tiede","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0008","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2015-10-675140","article-title":"Men with severe hemophilia in the United States: birth cohort analysis of a large national database","volume":"127","author":"Mazepa","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0009","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood-2015-01-528414","article-title":"Optimal treatment strategies for hemophilia: achievements and limitations of current prophylactic regimens","volume":"125","author":"Oldenburg","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0010","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1538-7836.2009.03703.x","article-title":"Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens","volume":"8","author":"Collins","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0011","doi-asserted-by":"crossref","first-page":"2970","DOI":"10.1182\/blood.2020009197","article-title":"Molecular determinants of the factor VIII\/von Willebrand factor complex revealed by BIVV001 cryo-electron microscopy","volume":"137","author":"Fuller","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0012","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1182\/blood-2016-04-713289","article-title":"Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A","volume":"128","author":"Pipe","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0013","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1182\/blood.2019001292","article-title":"BIVV001, a new class of factor VIII replacement for hemophilia A that is independent of von Willebrand factor in primates and mice","volume":"135","author":"Seth Chhabra","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0014","unstructured":"US Food and Drug Administration. ALTUVIIIO (efanesoctocog alfa) prescribing information. https:\/\/www.fda.gov\/media\/165594\/download. 2024. Accessed October 9, 2024."},{"key":"10.1016\/j.clinthera.2024.09.010_bib0015","unstructured":"Sobi. EMA validates marketing authorisation application for efanesoctocog alfa for treatment of haemophilia A. https:\/\/www.sobi.com\/en\/press-releases\/ema-validates-marketing-authorisation-application-efanesoctocog-alfa-treatment-haemophilia-2128255. 2023. Accessed October 9, 2024."},{"key":"10.1016\/j.clinthera.2024.09.010_bib0016","unstructured":"Sanofi. Press release: once-weekly ALTUVIIIO\u00ae approved in Japan as a new class of factor VIII therapy for hemophilia A. https:\/\/www.globenewswire.com\/news-release\/2023\/09\/25\/2748334\/0\/en\/Press-Release-Once-weekly-ALTUVIIIO-approved-in-Japan-as-a-new-class-of-factor-VIII-therapy-for-hemophilia-A.html. 2023. Accessed October 9, 2024."},{"key":"10.1016\/j.clinthera.2024.09.010_bib0017","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2209226","article-title":"Efanesoctocog alfa prophylaxis for patients with severe hemophilia A","volume":"388","author":"von Drygalski","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0018","series-title":"Research Triangle Park","article-title":"Conducting patient interviews within a clinical trial setting","author":"DiBenedetti","year":"2018"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0019","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/hae.13140","article-title":"Measurement properties of the Haem-A-QoL in haemophilia clinical trials","volume":"23","author":"von Mackensen","year":"2017","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0020","series-title":"Handbook of Disease Burdens and Quality of Life Measures","first-page":"1895","article-title":"Quality of life in hemophilia","author":"Mackensen","year":"2010"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.socscimed.2021.114523","article-title":"Sample sizes for saturation in qualitative research: a systematic review of empirical tests","volume":"292","author":"Hennink","year":"2022","journal-title":"Soc Sci Med"},{"issue":"Suppl 81","key":"10.1016\/j.clinthera.2024.09.010_bib0022","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/ejh.12581","article-title":"Optimising musculoskeletal care for patients with haemophilia","volume":"95","author":"Carcao","year":"2015","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0023","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13047-023-00611-5","article-title":"Decline in health-related quality of life and foot and ankle patient reported outcomes measures in patients with haemophilia and ankle haemarthropathy","volume":"16","author":"Wilkins","year":"2023","journal-title":"J Foot Ankle Res"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0024","first-page":"309","article-title":"Pain experience in hemophilia patients: a hermeneutic phenomenological study","volume":"4","author":"Rambod","year":"2016","journal-title":"Int J Community Based Nurs Midwifery"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0025","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/j.1365-2516.2006.01203.x","article-title":"Pain and functional limitations in patients with severe haemophilia","volume":"12","author":"van Genderen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0026","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.2147\/PPA.S87659","article-title":"Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study","volume":"9","author":"Forsyth","year":"2015","journal-title":"Patient Pref Adher"},{"key":"10.1016\/j.clinthera.2024.09.010_bib0027","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1186\/s12955-018-0908-9","article-title":"The impact of severe haemophilia and the presence of target joints on health-related quality-of-life","volume":"16","author":"O'Hara","year":"2018","journal-title":"Health Qual Life Outcomes"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291824002728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T20:00:28Z","timestamp":1733860828000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291824002728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":27,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0149291824002728"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Patient Experience With Efanesoctocog Alfa for Severe Hemophilia A: Results From the XTEND-1 Phase 3 Clinical Study Exit Interviews","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2024.09.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}